摘要
背景:到2019年底,新型冠状病毒病(COVID-19)的突然爆发已成为全球性威胁。之所以称为 COVID-19,是因为它是由 2019 年的新型冠状病毒(SARS-COV-2)引起的。 全世界共报告了 190 万例死亡和 8790 万例病例,迄今已治愈 4900 万例。科学家们正在努力寻找 COVID-19 的化疗药物和疫苗。在几种危险压力的组合中观察到 SARS-CoV-2 的突变,使它们更具抵抗力和益处。因此,为了分解病毒系统,需要检查疾病目标。 目的:在现今的综述中,对刺突蛋白的综合研究解释了新型冠状病毒的主要用途以及如何防止疾病病毒从感染者交叉传播到健康人。 方法: Covid-19 已被世界卫生组织 (WHO) 宣布为大流行病,因为它会在全球范围内导致死亡和严重疾病。 SARS-CoV-2 具有高度传染性;然而,新型冠状病毒的中间宿主尚不清楚。为了探索疾病的机制,病毒靶点之一,例如与人类细胞结合并通过改变其遗传结构引起疾病的刺突蛋白,这被认为是潜在的抑制剂。 结果:已表明SARS-CoV-2刺突的受体结合域(RBD)蛋白与血管紧张素转换酶2(ACE2)宿主受体的相互作用以及冠状病毒刺突蛋白的进一步复制导致其入侵宿主细胞。人类淋巴细胞抗原 6 复合物 Locus E (LY6E) 通过干扰人类基因、诱导刺突蛋白介导的膜融合来抑制 CoV 进入宿主细胞。一些天然配方也被证明可以防止刺突蛋白与宿主细胞结合。 结论:随着可抑制刺突蛋白-ACE2介导的膜融合的LY6E基因激活剂的开发,SARS-CoV-2治疗的新机会可能出现。现有的抗病毒融合抑制剂和针对刺突抗性的天然化合物可以作为进一步 SARS-CoV-2 药物制剂的模板。
关键词: COVID-19,刺突蛋白潜在冠状病毒靶点,基因改造,天然药物,交叉感染预防,ACE2。
图形摘要
Current Drug Targets
Title:Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents
Volume: 22 Issue: 17
关键词: COVID-19,刺突蛋白潜在冠状病毒靶点,基因改造,天然药物,交叉感染预防,ACE2。
摘要:
Background: By the end of 2019, the sudden outbreak of the novel coronavirus disease (COVID-19) has become a global threat. It is called COVID-19 because it was caused by the novel coronavirus (SARS-COV-2) in 2019. A total of 1.9 M deaths and 87.9 M cases have been reported all over the world, where 49M cases have recovered so far. Scientists are working hard to find chemotherapeutics and vaccines for COVID-19. Mutations in SARS-CoV-2 have been observed in a combination of several hazardous stresses, making them more resistant and beneficial. So to break down the viral system, the disease targets are examined.
Objective: In today's review, a comprehensive study of spike protein explains the main purpose of the novel coronavirus and how to prevent the spread of the disease virus cross-transmission from infected to a healthy person.
Methods: Covid-19 has already been declared a pandemic by the World Health Organization (WHO) due to its result in causing death and severe illness globally. SARS-CoV-2 is highly contagious; however, the intermediate host of the novel coronavirus is not clear. To explore the mechanisms of disease, one of the viral targets, such as the spike protein that binds to human cells and causes the disease by altering its genetic structure which is considered along with potential inhibitors.
Results: It has been shown that the interaction of receptor-binding domain (RBD) protein of SARS- CoV-2 spike and the angiotensin-converting enzyme 2 (ACE2) host receptor and further replication of coronavirus spike protein causes its invasion in the host cell. The human Lymphocyte antigen 6 complex, Locus E (LY6E), inhibits the entry of CoV into host cells by interfering with the human gene, inducing spike protein-mediated membrane fusion. Some natural formulations have also been shown to prevent spike protein from binding to the host cell.
Conclusion: With the development of the LY6E gene activator that can inhibit spike protein- ACE2-mediated membrane fusion, new opportunities for SARS-CoV-2 treatment may emerge. Existing antiviral fusion inhibitors and natural compounds targeting spike resistance can serve as a template for further SARS-CoV-2 drug formulation.
Export Options
About this article
Cite this article as:
Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents, Current Drug Targets 2021; 22 (17) . https://dx.doi.org/10.2174/1389450122666210309105820
DOI https://dx.doi.org/10.2174/1389450122666210309105820 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research The Potential Role of Statins in Pneumonia
Current Respiratory Medicine Reviews Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Atrial Fibrillation During or After TAVI: Incidence, Implications and Therapeutical Considerations
Current Pharmaceutical Design Odontogenic Infections in the Etiology of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Burden of Bronchiectasis in Indigenous Peoples - How Can it be Improved?
Current Pediatric Reviews Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Resistin-Like Molecule-α Causes Lung Injury in Rats with Acute Pancreatitis by Activating the PI-3K/Akt-NF-κB Pathway and Promoting Inflammatory Cytokine Release
Current Molecular Medicine Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders
Current Molecular Medicine The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Insulin Action on the Human Placental Endothelium in Normal and Diabetic Pregnancy
Current Vascular Pharmacology III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Current Pharmaceutical Design Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Anti-inflammatory Effects of Tacrolimus in a Rat Model of Acute Pancreatitis
Medicinal Chemistry Smart Polymers for Controlled Delivery of Proteins and Peptides: A Review of Patents
Recent Patents on Drug Delivery & Formulation